COCP Cocrystal Pharma Inc.

2.1
-0.09  -4%
Previous Close 2.19
Open 2.07
Price To Book 0.9
Market Cap 66,403,357
Shares 31,620,646
Volume 1,238
Short Ratio
Av. Daily Volume 9,058

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a initial data released January 22, 2019. 66% (SVR12). Full data to be presented in 2019.
CC-31244
Hepatitis C
Phase 1 trial to be initiated in 2019.
CC-42344
Influenza
Phase 2a commencement of enrolment in Hong Kong trial announced May 20, 2019. Interim data 4Q 2019.
CC-31244
Hepatitis C

Latest News

  1. Do Insiders Own Shares In Cocrystal Pharma, Inc. (NASDAQ:COCP)?
  2. Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
  3. Cocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update
  4. Cocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook
  5. Cocrystal Pharma Announces Closing of Private Placement
  6. Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
  7. Robbins Arroyo LLP: Shareholder Lawsuit Says Cocrystal Pharma, Inc. (COCP) Misled Shareholders
  8. Cocrystal Announces Board Changes
  9. 4 Pharma Stocks Raising Eyebrows (1/3/19)
  10. Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
  11. Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
  12. WeissLaw LLP: Cocrystal Pharma, Inc. is the Subject of a Legal Investigation
  13. DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses of $100,000 to Contact the Firm
  14. FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cocrystal Pharma, Inc. f/k/a/ BioZone Pharmaceuticals, Inc. (COCP) and Lead Plaintiff Deadline – November 19, 2018
  15. Detailed Research: Economic Perspectives on Cocrystal Pharma, Genius Brands International, Gemphire Therapeutics, Global Water Resources, Infrastructure and Energy Alternatives, and Condor Hospitality Trust — What Drives Growth in Today's Competitive Landscape
  16. CLASS ACTION UPDATE for COCP, JT and DY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  17. DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
  18. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COCP, ABBV, CHGG, HON and DY
  19. COCP DEADLINE NOTICE ALERT: Rosen Law Firm Reminds Cocrystal Pharma, Inc. Investors of Important Nov. 19 Deadline in First Filed Case – COCP